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Fanconi Anemia (FA) is a rare recessive disease characterized
by congenital abnormalities, bone marrow failure, and cancer
susceptibility. The FA proteins and the familial breast cancer
susceptibility gene products, BRCA1 and FANCD1/BRCA2,
function cooperatively in the FA-BRCA pathway to repair dam-
aged DNA and to prevent cellular transformation. Activation
of this pathway occurs via the mono-ubiquitination of the
FANCD2 protein, targeting it to nuclear foci where it co-local-
izes with FANCD1/BRCA2, RAD51, and PCNA. The regulation
of the mono-ubiquitination of FANCD2, as well as its function
in DNA repair remain poorly understood. In this study, we have
further characterized the interaction between the FANCD2 and
PCNAproteins.We have identified a highly conserved, putative
FANCD2 PCNA interaction motif (PIP-box), and demonstrate
that mutation of this motif disrupts FANCD2-PCNA binding
and precludes the mono-ubiquitination of FANCD2. Conse-
quently, the FANCD2 PIP-box mutant protein fails to correct
the mitomycin C hypersensitivity of FA-D2 patient cells. Our
results suggest that PCNAmay function as amolecular platform
to facilitate themono-ubiquitination of FANCD2and activation
of the FA-BRCA pathway.
Fanconi anemia (FA)2 is a rare recessive disorder character-
ized by developmental abnormalities, progressive bonemarrow
failure, and pronounced cancer susceptibility (1). FA patients
are particularly susceptible to early-onset acute myelogenous
leukemia and squamous cell carcinoma of the head, neck, and
gynecologic regions (2). FA patient cells are hypersensitive to
the clastogenic effects of DNA cross-linking agents, e.g. mit-
omycin C (MMC), and agents that inhibit DNA replication,
e.g. aphidicolin (APH) (3, 4). There are currently thirteen
genetically defined FA complementation groups (A, B, C,
D1, D2, E, F, G, I, J, L, M, and N), and all thirteen genes have
been identified (5).
A central step in the activation of the FA-BRCA pathway is
the mono-ubiquitination of the FANCD2 and FANCI proteins,
catalyzed by the core FAE2/E3 holoenzyme complex (5, 6). The
mono-ubiquitination of FANCD2 and FANCI signals their
translocation to discrete nuclear foci, where they co-localize
with the BRCA1 andRAD51DNA repair proteins, as well as the
major cellular DNA polymerase processivity factor PCNA (3, 4,
7–9). Several studies have suggested an important role for the
FA-BRCA pathway in a DNA replication-associated DNA
repair process, e.g. homologous recombination (HR), and/or
translesion DNA synthesis (TLS) (3, 4, 10–12). Accordingly,
additional proteins with established roles in the DNA replica-
tion stress response, including ATR, CHK1, HCLK2, and RPA,
modulate DNA damage-inducible FANCD2mono-ubiquitina-
tion (13–15). Our understanding of the regulation of this criti-
cal post-translational modification, however, is incomplete.
We, and others (4, 7) have previously reported an association
between FANCD2 and PCNA. FANCD2 and PCNA co-localize
in nuclear foci following treatment with agents that inhibit
DNA replication. Like FANCD2, PCNA is mono-ubiquitinated
following exposure to DNA-damaging agents (16, 17). While
FANCD2 and PCNA are mono-ubiquitinated by different E3
ubiquitin ligases, FANCL and RAD18 (16–19), respectively,
both proteins are de-ubiquitinated by the USP1 enzyme (20,
21). The functional significance of the FANCD2-PCNA inter-
action, however, has not been determined.
In addition to its role as a DNA polymerase processivity fac-
tor, PCNA interacts with many DNA repair proteins, e.g.
MSH3,XPG, and p21Cip1/Waf1 (22). These interactions typically
occur in a hydrophobic pocket of the PCNA homotrimer,
termed the interdomain connecting loop (ICL). Proteins that
interact with the PCNA ICL harbor a highly conserved PCNA-
binding motif called the PIP-box, defined by the amino acid
sequence QXXhXXaa, where h represents amino acids with
moderately hydrophobic side chains, e.g. leucine, isoleucine, or
methionine (L, I, M), a represents amino acids with highly
hydrophobic, aromatic side chains, e.g. phenylalanine and tyro-
sine (F, Y), and X is any amino acid (23).
Here, we describe an important functional interaction
between FANCD2 and PCNA.We have identified a highly con-
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served putative PIP-box in FANCD2, and demonstrate that
mutation of this motif disrupts the FANCD2-PCNA interac-
tion, and precludes both the spontaneous and DNA damage-
induciblemono-ubiquitination of FANCD2. Consequently, the
FANCD2 PIP-box mutant fails to correct the MMC hypersen-
sitivity of FA-D2 patient-derived cells. However, the mutant
protein retains the ability to localize to chromatin, interact with
FANCE, and undergo DNA damage-inducible phosphoryla-
tion. Our results suggest that PCNA may act as a molecular
platform for the mono-ubiquitination of FANCD2 and for the
activation of the FA-BRCA pathway.
EXPERIMENTAL PROCEDURES
Cell Culture, Plasmids, and Site-directed Mutagenesis—
COS-7, PD20F, and HCT116 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 12%
(v/v) fetal bovine serum. PD20F pMMP-FANCD2 cells were
maintained in DMEM supplemented with 1 g/ml puromycin.
PD20F plus 6xHis/V5-FANCD2 were maintained in DMEM
supplemented with 200 g/ml G418. The FANCD2 PIP
cDNA was generated by site-directed mutagenesis of the wild-
type FANCD2 cDNA by PCR-based site-directed mutagenesis
using 74-mer forward and reverse oligonucleotides, containing
a total of 8 mismatches (underlined): CAG CAA ATA CGA
AAACTCTTCTAT4GCGCAAATAGCAAAACTCGCC
GCT. pDEST40 (Invitrogen) is a pcDNA3-based plasmid for
the expression of C terminus 6xHis/V5 fusion proteins. pMT5-
FLAG-p21 (Addgene) is an N terminus FLAG-tagged p21
mammalian expression vector.
Immunoblotting and Immunoprecipitations—Whole-cell
extracts (WCE) for immunoblotting were prepared by lysis of
cells in 2% SDS lysis buffer with boiling. For immunoprecipita-
tions (IP), lysates were prepared in radioimmune precipitation
assay buffer or NETN buffers supplemented with protease and
phosphatase inhibitors (24). Between 400 and 1000 g of total
protein were used per IP reaction. For the Ni2 pull-down
experiments, whole-cell lysates were prepared in 50 mM Tris,
pH 7.8, 300 mM NaCl, 10 mM imidazole, 0.5% (v/v) Nonidet
P-40, supplemented with protease and phosphatase inhibitors,
and incubated with Ni2 beads for 1 h at 4 °C. The GST pull-
down experiments were performed as previously described
(25), and whole-cell lysates were incubated with 10 g of
recombinant GST-Empty or GST-PCNA for 1 h at 4 °C. Pro-
teins were resolved using NuPAGE 3–8% (w/v) Tris-acetate or
4–12% (w/v) Bis-Tris (MOPS) gels (Invitrogen). The following
antibodies were used: rabbit polyclonal antisera against
FANCD2 (NB100–182, Novus Biologicals), PCNA (FL-261;
Santa Cruz Biotechnology), FLAG (F7425; Sigma), and histone
H2A (acidic patch) (07-146,Millipore), andmousemonoclonal
sera against DNA polymerase  catalytic subunit (610972; BD
Biosciences), FANCD2 (FI-17; Santa Cruz Biotechnology),
PCNA (PC10; Santa Cruz Biotechnology), -tubulin (MS-581-
PO, Neomarkers), and V5 (Invitrogen). Images were analyzed,
and band intensities quantified using ImageJ.
 Phosphatase Treatment—Cells were lysed in modified 
phosphatase reaction buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 0.1 mM EGTA, 2 mM dithiothreitol, 2 mM MnCl2, 0.01%
(v/v) Brij 35, 0.5% (v/v) Nonidet P-40) supplemented with pro-
tease inhibitors, with sonication for 10 s. Approximately 10
units of  phosphatase per g of protein were incubated at
30 °C for 1 h, prior to loading.
Cellular Subfractionation and Immunocytochemistry—Cells
were grown in 15-cm2 dishes, incubated in the absence or pres-
ence of 120 nMMMC for 24 h, washedwith phosphate-buffered
saline, and harvested in S1 hypotonic lysis buffer (10 mM Tris-
HCl, pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 10 mM -mercapto-
ethanol). Nuclear soluble proteins (S2 fraction) were extracted
with a high-salt buffer (15 mM Tris-HCl, pH 7.4, 1 mM EDTA,
500 mM NaCl, 1 mM MgCl2, 10% glycerol, 10 mM -mercapto-
ethanol, plus protease inhibitors). To enrich for chromatin-as-
sociated proteins, salt-extracted pellets were treated with 3
units/l of micrococcal nuclease for 20 min at room tempera-
ture in nuclease reaction buffer (20 mM Tris-HCl, pH 7.4, 100
mM KCl, 2 mM MgCl2, 1 mM CaCl2, 0.3 M sucrose, 0.1% Triton
X-100, plus protease inhibitors). FANCD2 immunocytochem-
istry was performed as described previously (3, 4).
DNA Damage Assays—MMC sensitivity and chromosome
breakage assays were performed as described previously (4, 26).
Statistical analysis of total chromosome gaps and breaks data
were carried out using the Student’s t-test for equal or unequal
variance. Variance for each data set was determined using the
sample variance F-test. Cells were X-irradiated using a Philips
250 orthovoltage unit at2 Gy/min in the Irradiation Core of
the University of Michigan Cancer Center.
RESULTS
Further Characterization of the FANCD2-PCNA Interaction—
Using immunoprecipitation approaches, we sought to expand
upon previous findings of an association between FANCD2 and
PCNA in DNA damage-inducible nuclear foci (4, 7). First,
whole-cell lysates were prepared from HeLa cells stably
expressing HA-tagged PCNA, untransfected or transiently
transfectedwith a positive control FLAG-tagged p21 construct.
HA-PCNA co-immunoprecipitated with FLAG-p21 as well as
both non- and mono-ubiquitinated FANCD2 (Fig. 1A). Next,
we generated a FA-D2 (FANCD2-null) patient cell line stably
expressing 6xHis/V5-tagged FANCD2 (Fig. 1B). Expression of
6xHis/V5-FANCD2 rescued the MMC hypersensitivity of
these cells (results not shown). Using a Ni-nitrilotriacetic acid
pull-down approach, endogenous PCNA co-immunoprecipi-
tated with 6xHis/V5-FANCD2 from these cells (Fig. 1B, lower
panel, lane 3). To analyze the interaction between endogenous
FANCD2 and PCNA in chromatin, HCT116 cells were irradi-
ated with 40 J/m2 UV-C, fractionated in low and high salt lysis
buffers, and sonicated briefly to release chromatin-bound pro-
teins (24).We observed an enrichment formono-ubiquitinated
FANCD2 in the sonicated high salt cellular fraction, as
expected (27) (Fig. 1C, upper panel, lanes 3 and 6). A mouse
monoclonal anti-PCNA antibody, but not mouse IgG, exclu-
sively co-immunoprecipitated FANCD2 from both high salt
fractions (Fig. 1C,middle panel, lanes 5 and 6). The specificity
of the anti-PCNA mouse monoclonal antibody for PCNA
immune complexes was confirmed by immunoblotting with an
anti-PCNA rabbit polyclonal antibody (Fig. 1C, lower panel). In
a reciprocal approach, a rabbit polyclonal anti-FANCD2 anti-
body, but not rabbit serum, preferentially immunoprecipitated
PCNA-dependent Activation of the FA-BRCA Pathway
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PCNA from chromatin fractions prepared from untreated and
UV-irradiated HCT116 cells (supplemental Fig. S1, lower
panel, lanes 3 and 4). In support of a direct interaction between
FANCD2 and PCNA, GST-PCNA, and not GST alone, bound
to 6xHis/V5-FANCD2 overexpressed in COS-7 cells (Fig. 1D,
lanes 6 and 8). For this experiment, COS-7 cells overexpressing
FLAG-p21 was used as a positive control (Fig. 1D, lane 8).
FANCD2 Contains a Highly Conserved Putative PCNA Inter-
action Motif—We identified two putative PIP-box motifs in
FANCD2: one at amino acids 527–534 and a second at amino
acids 1063–1070. The PIP-box at amino acids 527–534 demon-
strated high conservation and was selected for further analysis.
The four essential FANCD2 PIP527–534-box amino acids were
mutated to alanines (Fig. 2A), and the pMMP-FANCD2 PIP
retroviral vector generated. PD20F (FA-D2) patient cells were
transducedwith pMMP-FANCD2PIP, to generate the PD20F
pMMP-FANCD2 PIP cell line. To analyze the effect of muta-
tion of the FANCD2 PIP-box on the FANCD2-PCNA interac-
tion, PCNA immune complexes were immunoprecipitated
from PD20F pMMP-Empty, -FANCD2 wt, -FANCD2 K561R
(that cannot be mono-ubiquitinated) (3), and -FANCD2 PIP
cells, and immunoblotted with anti-FANCD2. As expected,
FANCD2 wt readily co-immuno-
precipitated with PCNA (Fig. 2B).
FANCD2 K561R also co-immuno-
precipitated with PCNA, albeit less
efficiently (3-fold reduction) than
FANCD2 wt (Fig. 2B and supple-
mental Fig. S2A). Finally, negligible
levels of FANCD2 PIP co- immu-
noprecipitated with PCNA (Fig. 2B
and supplemental Fig. S2A). Immu-
noblotting with a rabbit polyclonal
anti-PCNA antibody confirmed the
presence of equal amounts of PCNA
immune complexes in all four cell
lines (Fig. 2B).
Next, COS-7 cells were tran-
siently transfected with 6xHis/V5-
FANCD2wt, -FANCD2K561R, and
-FANCD2 PIP mammalian ex-
pression constructs. Similar to
that observed above, 6xHis/V5-
FANCD2 wt co-immunoprecipi-
tated with PCNA (Fig. 2C). 6xHis/
V5-FANCD2 K561R also co-immu-
noprecipitated with PCNA, although
again less efficiently than 6xHis/V5-
FANCD2wt (Fig. 2C and supplemen-
tal Fig. S2B). Finally, negligible levels
of 6xHis/V5-FANCD2 PIP co-im-
munoprecipitated with PCNA (Fig.
2C). When corrected for total
6xHis/V5-FANCD2 PIP protein
levels, this corresponded to an
approximate 9-fold reduction in
association between PCNA and
6xHis/V5-FANCD2 PIP, com-
pared with 6xHis/V5-FANCD2 wt (supplemental Fig. S2B).
The FANCE protein has been proposed to form a molecular
bridge between the core FA complex and FANCD2, and has
been demonstrated to bind directly to FANCD2 (28). To ana-
lyze the effect of mutation of the FANCD2 PIP-box on the
FANCD2-FANCE interaction, we transiently transfected
PD20F pMMP-Empty, -FANCD2 wt, -FANCD2 K561R, and
-FANCD2 PIP cells with a FLAG-tagged FANCE construct,
and examined the association between FANCD2 and FLAG-
FANCE (Fig. 2D). The use of an epitope-tagged FANCE con-
struct was required for this experiment because of the absence
of a suitable commercially available FANCE antibody. When
normalized for total FANCD2 protein levels, approximately
equal amounts of FANCD2wt, FANCD2K561R, and FANCD2
PIP co-immunoprecipitated with FLAG-FANCE, indicating
that the FANCD2 PIP mutant protein retains the ability to
associate with FANCE (Fig. 2D and supplemental Fig. S2C).We
also sought to determine if mutation of the FANCD2 PIP-box
disrupted the interaction between FANCD2 and FANCI. How-
ever, we were unable to co-immunoprecipitate FANCD2 wt
and FANCI, precluding us from addressing this question. Col-
lectively, these results suggest that the interaction between
FIGURE 1. Co-immunoprecipitation of FANCD2 and PCNA. A, HeLa cells stably expressing HA-PCNA were
untransfected or transiently transfected with the mammalian expression vector pMT5-FLAG-p21. HA-PCNA
immune complexes were immunoprecipitatedwith anti-HA agarose, resolved, and immunoblottedwith anti-
FANCD2, -PCNA, -FLAG, and -p21 antibodies. B, PD20F pDEST40-FANCD2 cells, stably expressing 6xHis/V5-
FANCD2, were treated with 20 J/m2 UV irradiation and WCE prepared 4 h later. WCE were resolved and
immunoblottedwith anti-FANCD2 and anti-V5 antibodies. For theNi2pull-down,WCE fromPD20FpDEST40-
FANCD2 cells were incubatedwith protein A/G-agarose or Ni2 beads for 1 h at 4 °C, and bound proteins were
immunoblotted with anti-PCNA and anti-V5 antibodies. C, HCT116 cells were treated with 40 J/m2 UV irradia-
tion and 4 h later lysed in NETN lysis buffer containing 100mM or 420mMNaCl without and with sonication to
yield S100, S420, and P420 fractions, respectively. Lysates were incubated with anti-PCNA antibody or control
mouse IgG. Immunoprecipitateswere analyzedby immunoblottingwith anti-FANCD2andanti-PCNAantibod-
ies. D, COS-7 cells were transiently transfected with the mammalian expression vectors pDEST40-FANCD2 or
pMT5-FLAG-p21 and WCE incubated with GST-Empty and GST-PCNA recombinant proteins. Bound proteins
were resolved and immunoblotted with anti-V5 and anti-FLAG antibodies. IP, immunoprecipitation. PD, pull-
down. ND, no DNA.
PCNA-dependent Activation of the FA-BRCA Pathway
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FANCD2 and PCNA is mediated by a putative FANCD2 PIP-
box that is dispensable for FANCD2-FANCE binding.
Mutation of the FANCD2 PIP-box Motif Abrogates FANCD2
Mono-ubiquitination—Next, we examined the effects of muta-
tion of the FANCD2 PIP-box on FANCD2 mono-ubiquitina-
tion. PD20F pMMP-Empty, -FANCD2 wt, -FANCD2 K561R,
and -FANCD2 PIP cells were exposed to 1.0MAPH for 24 h,
60 J/m2 UV irradiation, or 15 Gy X-irradiation. Strong induc-
tion of wt FANCD2 mono-ubiquitination was observed for all
treatments. For example, exposure to 1.0 M APH for 24 h
increased the FANCD2-Ub:FANCD2 ratio 2-fold (Fig. 3A).
However, like FANCD2 K561R, the FANCD2 PIP-box mutant
protein failed to undergo both spontaneous or DNA damage-
inducible mono-ubiquitination (Fig. 3, A–C). Conversely, UV-
inducible PCNAmono-ubiquitination was observed for all cell
lines (Fig. 3B).
We next examined the ability of the FANCD2 PIP-box
mutant to undergo UV-inducible, ATR-mediated phosphoryl-
ation (13, 29). Whole-cell lysates prepared from untreated and
UV-irradiated PD20F pMMP-FANCD2 wt and -FANCD2
PIP cells were incubated in the absence or presence of  phos-
phatase. As expected,  phosphatase treatment accelerated the
migration of FANCD2 wt (Fig. 3D, lanes 1–4). Similarly, 
phosphatase treatment accelerated the migration of both
untreated and UV-irradiated FANCD2 PIP (Fig. 3D, lanes
5–8). Collectively, these results indicate that the FANCD2 PIP-
box mutant fails to undergo both
spontaneous and DNA damage-
inducible mono-ubiquitination, yet
remains competent for ATR-medi-
ated phosphorylation.
The FANCD2 PIP-box Mutant
Localizes to Chromatin Yet Fails to
FormNuclear Foci—Wenext exam-
ined the subcellular localization of
the FANCD2 PIP mutant protein.
Cells were lysed in a hypotonic
buffer to extract cytoplasmic pro-
teins (S1). The remaining pellets
were lysed in a high-salt buffer to
extract soluble nuclear proteins
(S2). Salt-extracted pellets were
subsequently treated with micro-
coccal nuclease to release chro-
matin-associated proteins, char-
acterized by the presence of the
nucleosomal histone H2A (S3) (30).
We detected mono-ubiquitinated
FANCD2 in the S2 and S3 fractions,
in the absence and presence of
MMC, as expected (Fig. 4A, upper
panel, lanes 9–12). However, we
also detected both non-ubi-
quitinated FANCD2 K561R and
FANCD2 PIP in all three frac-
tions, in the absence and presence
of MMC (Fig. 4A), indicating that
the FANCD2 PIPmutant protein
remains competent for chromatin localization. A similar
observation has previously been described for FANCD2
K561R (31).
We next examined the ability of the FANCD2 PIP-box
mutant protein to assemble into discrete nuclear foci. Fol-
lowing exposure to APH, FANCD2 wt formed discrete
nuclear foci as previously reported (3, 4) (Fig. 4B). However,
like FANCD2 K561R (3), FANCD2 PIP failed to form
nuclear foci in the absence or presence of APH. Instead, we
consistently observed non-punctate staining patterns,
including diffuse nuclear as well as concentrated nucleolar
staining (Fig. 4B).
FANCD2 Mono-ubiquitination Promotes Its Stabilization
in Chromatin—We next determined the protein half-lives of
FANCD2-Ub, FANCD2 wt, FANCD2 K561R, and FANCD2
PIP. Cells were exposed to the translation inhibitor cyclo-
heximide and protein levels monitored over a 24 h period.
FANCD2 K561R and FANCD2 PIP exhibited significantly
shorter half-lives than both FANCD2-Ub and FANCD2 wt.
For example, 3 h following exposure to cycloheximide
FANCD2 wt, K561R, and PIP protein levels had decreased
by 23, 38, and 81%, respectively (Fig. 5, A and B). In con-
trast, wild-type FANCD2-Ub protein levels increased28%,
and remained elevated 24 h following the addition of cyclo-
heximide. These results indicate that the mono-ubiquitina-
tion of FANCD2 promotes its stabilization in chromatin, and
FIGURE 2.TheFANCD2PIP-boxmotif is required for the FANCD2-PCNA interaction.A, BLAST alignment of
FANCD2 homologues demonstrating conservation of the human FANCD2 PIP-box, and mutation strategy.
B, decreased association of the FANCD2 PIP mutant with PCNA. WCE were incubated with anti-PCNA anti-
body, and immune complexes were resolved and immunoblotted with anti-FANCD2 and anti-PCNA antibod-
ies. C, COS-7 cells were transiently transfectedwith the indicated pDEST40-FANCD2 constructs. 48 h later,WCE
were prepared, incubated with anti-PCNA antibody, and immune complexes were resolved and immuno-
blotted with anti-V5 antibody. D, association of the FANCD2 PIP mutant protein with FANCE. Cells were
transiently transfected with the pEAK8-FLAG-FANCE construct (28) and 48 h later WCE incubated with anti-
FLAG antibody. Immune complexeswere resolved and immunoblottedwith anti-FANCD2 and anti-FLAG anti-
bodies. IP, immunoprecipitation.
PCNA-dependent Activation of the FA-BRCA Pathway
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that mutation of Lys-561 and the
PIP-box significantly reduces the
protein half-life.
The FANCD2 PIP-box Motif
Mutant Fails to Correct the Cellu-
lar Phenotypes of FA-D2 Patient
Cells—We next determined if the
FANCD2PIPmutant could rescue
theMMChypersensitivity of PD20F
cells. In contrast to FANCD2wt, the
FANCD2 PIPmutant failed to res-
cue the MMC sensitivity of PD20F
cells. For example, at 60 nMMMC, a
2.4-fold increase in sensitivity (p 
0.05) to the lethal effects of MMC
was observed for PD20F pMMP-
FANCD2 PIP cells compared with
PD20F pMMP-FANCD2 wt cells
(Fig. 6A). We also measured the
frequency of chromosome gaps,
breaks, and radial formations in
metaphase spreads prepared from
cells treated with APH or MMC. As
expected, exposure to APH and
MMC induced significantly ele-
vated levels of chromosome aberra-
tions in PD20F pMMP-Empty cells,
6.2-fold (p  0.0001) and 2.1-fold
(p  0.0093), respectively, com-
pared with untreated cells (Fig. 6B).
Expression of FANCD2 wt cor-
rected the elevated APH- (p 
0.0315) and MMC- (p  0.001)
induced chromosome aberrations
of PD20F cells.However, expression
of either FANCD2 K561R or
FANCD2 PIP failed to correct the
elevated frequency of APH- and
MMC-induced chromosome aber-
rations. Like PD20F pMMP-Empty,
a 6.0-fold (p  0.0001) and 2.4-fold
(p  0.0026) increase in chromo-
some aberrations was observed for
PD20F pMMP-FANCD2 PIP cells
following treatment with APH and
MMC, respectively, compared with
untreated cells (Fig. 6B). Finally,
using flow cytometry, we examined
cell cycle progression in the absence
or presence of MMC. Like PD20F
pMMP-Empty and -FANCD2
K561R cells, PD20F pMMP-
FANCD2 PIP cells displayed a
prolonged accumulation in G2
phase of the cell cycle following
exposure to MMC. For example,
a 2-fold greater proportion of
PD20F pMMP-FANCD2 PIP cells
FIGURE 3. The FANCD2 PIP-box motif is required for both spontaneous and DNA damage-inducible
FANCD2mono-ubiquitination. A, cells were untreated (NT) or exposed to 1.0 M APH for 24 h (APH), and
WCE were immunoblotted with the indicated antibodies. The catalytic subunit of DNA Pol was used as a
protein loading control. B, cells were untreated (NT) or exposed to 60 J/m2 UV irradiation (UV), and 4 h later
whole-cell lysates were prepared and immunoblotted with the indicated antibodies. C, cells were
untreated (NT) or exposed to 15 Gy X-irradiation (X-IR). Whole-cell lysates were prepared 3 h post-irradi-
ation and immunoblotted with the indicated antibodies. D, PD20F pMMP-FANCD2 wt and -FANCD2 PIP
were untreated (NT) or exposed to 60 J/m2 UV irradiation (UV), and 4 h later, whole-cell lysates were
prepared and incubated in the presence or absence of  phosphatase (-P Pase), prior to immunoblotting
with the indicated antibodies.
FIGURE 4. The FANCD2 PIP-box mutant localizes to chromatin yet fails to assemble into nuclear foci.
A, cellswere incubated in the absence andpresence of 120nMMMC for 18h, fractionated into cytoplasmic (S1),
soluble nuclear (S2), and chromatin-associated fractions (S3), and immunoblottedwith antibodies to FANCD2,
-tubulin, PCNA, and H2A. B, FANCD2 PIP-box mutant fails to assemble into nuclear foci. PD20F pMMP-
FANCD2 wt and pMMP-FANCD2 PIP cells were incubated in the absence or presence of 1.0 M APH for 24 h,
fixed, and stained with rabbit polyclonal anti-FANCD2 E35 (green) antibody, and counterstained with 4,6-
diamidino-2-phenylindole (DAPI) (blue).
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accumulated in G2/M following exposure to MMC, compared
with PD20F pMMP-FANCD2 wt cells (Fig. 6C). Collectively
these results strongly suggest that the FANCD2 PIP-box is
essential for the function of
FANCD2 in the cellular DNA dam-
age response.
DISCUSSION
In support of an important role
for the FA-BRCA pathway in a
S-phase DNA repair process, both
spontaneous andDNAcrosslink-in-
duced FANCD2 mono-ubiquitina-
tion and nuclear foci formation
occur almost exclusively during
S-phase (9, 32, 33). Thus, it is likely
that a stalled or collapsed DNA rep-
lication fork is a major stimulus
for the mono-ubiquitination of
FANCD2. The mechanism by
which FANCD2 is recruited to dam-
aged DNA replication forks has not,
however, been determined. Here,
we describe an important interac-
tion between the FANCD2 and
PCNA proteins. We demonstrate
that FANCD2 and PCNA associate
in chromatin, and that this associa-
tion is dependent on a highly con-
served FANCD2 PIP-box motif.
Furthermore, disruption of this
motif abrogates both spontane-
ous and DNA damage-inducible
FANCD2 mono-ubiquitination.
Our results suggest that the asso-
ciation between PCNA and
FANCD2 may be an important
prerequisite for the mono-ubiquiti-
nation of FANCD2 and, conse-
quently, its DNA repair function. A
similar auxiliary role for PCNA, also
mediated via PIP-box interactions,
has been established for several
DNA repair enzymes including
MSH3, XPG, and XPV/Pol  (34–
37). The association of FANCD2
with PCNA in a DNA damage sur-
veillance capacity represents an
attractive model for the localization
of FANCD2 to sites of DNAdamage
encountered by theDNA replisome.
That the mutation of the
FANCD2 PIP-box completely abro-
gated both spontaneous and DNA
damage-inducible FANCD2 mono-
ubiquitination was unexpected. To
our knowledge, only one other
FANCD2 mutation, that of the site
of ubiquitin conjugation itself, Lys-561, has been described that
leads to a complete loss of FANCD2 mono-ubiquitination (3).
We could not rule out the possibility that a change in protein
FIGURE 5.Themono-ubiquitinationof FANCD2promotes its chromatin stabilization.A, cells were treated
with cycloheximide (CHX) and whole-cell lysates immunoblotted with antibodies against FANCD2, PCNA, and
-tubulin. B, FANCD2 protein band intensities from Fig. 6A were quantified using ImageJ and plotted.
FANCD2-Ub (E), FANCD2 wt (non-ubiquitinated) (F), FANCD2 K561R (), FANCD2 PIP (f).
FIGURE6.TheFANCD2PIP-boxmutantfails torescuethecellularphenotypesofPD20F (FA-D2) cells.A, PD20F
(FA-D2) pMMP-Empty (E), -FANCD2wt (F), -FANCD2K561R (), and -FANCD2PIP (f)were treatedwithMMC for
10–14 days. Error bars represent the S.E. from triplicatemeasurements, and are smaller than the dimensions of the
symbols for several points. This experiment was performed three times with similar findings. B, same cells were
untreated (white bars) or exposed to 0.2M APH (gray bars) or 30 nMMMC (black bars) for 24 h, and chromosome
aberrations quantified. At least 30 metaphases were scored for each treatment. Error bars indicate the S.E. This
experimentwas performed three timeswith similar findings.C, for theG2 accumulation assay cellswere untreated
(NT) or exposed to 75 nMMMC for 48 h, fixed, stainedwith propidium iodide, and analyzed by flow cytometry.
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folding underlies the inability of the FANCD2 PIP-box mutant
to undergo mono-ubiquitination, as the PIP-box is proximal to
Lys-561 (3). Thus, a localized alteration in protein folding may
preclude access of the FA E2/E3 holoenzyme to Lys-561. Sev-
eral lines of evidence, however, argue against a gross structural
alteration. First, like FANCD2 wt, the FANCD2 PIP mutant
retained the ability to interact with FANCE, a core FA complex
protein previously demonstrated to bind directly to FANCD2
(28). Second, the FANCD2 PIP mutant protein underwent
DNA damage-inducible phosphorylation (13, 29). Third, the
FANCD2 PIPmutant protein localized to chromatin. These
results suggest that the mutant protein retains structural
integrity and at least partial functionality. Nevertheless, we
cannot rule out the possibility of a localized effect, or that
mutation of the PIP-box precludes the interaction of
FANCD2 with a protein, other than PCNA, required for its
efficient mono-ubiquitination.
The mono-ubiquitination of FANCD2 has previously been
hypothesized to be required for its targeting to chromatin (27).
However, in this study, albeit using a different subcellular frac-
tionation protocol, we detected non-ubiquitinated FANCD2
K561R and FANCD2 PIP proteins in chromatin. We propose
that mono-ubiquitination stabilizes FANCD2 in chromatin,
and that non-ubiquitinated FANCD2 fails to be retained in
chromatin. In support of a chromatin-dependent FANCD2
mono-ubiquitinationmodel, the FANCD2 E2 ubiquitin-conju-
gating enzyme UBE2T (38) has been demonstrated to be con-
stitutively chromatin-localized, independent of DNA damage
or cell cycle stage (31). Furthermore, the FAcore complex local-
izes to chromatin, and its E3 ubiquitin ligase activity is depend-
ent on its DNA damage-induced chromatin localization (31,
39). Thus, we hypothesize that the association between
FANCD2 and PCNAmay facilitate the FA E2/E3 holoenzyme-
mediated mono-ubiquitination of FANCD2, and its stabiliza-
tion and retention in chromatin until USP1-mediated de-ubiq-
uitination and chromatin release (40). Consistent with this, we
have also demonstrated that mono-ubiquitinated FANCD2
displays a longer protein half-life than FANCD2 K561R and, in
particular, FANCD2 PIP. Mono-ubiquitin may serve as a
molecular adaptor between PCNA-associated FANCD2 and an
as yet unidentified ubiquitin-binding domain (UBD)-contain-
ing chromatin-associated protein. In support of this hypothesis,
Matsushita et al. (41) demonstrated that a chicken DT40
FANCD2-Ub chimeric protein harboring an I44A mutation in
the essential hydrophobic patch of ubiquitin (that disrupts
ubiquitin-UBD binding) could only weakly complement the
cisplatin sensitivity of fancd2 cells. Several candidate chroma-
tin-associated ubiquitin receptors exist, including XPV/Pol ,
REV1, or one of the core FA complex proteins.
An important FANCD2 mono-ubiquitination-independent
function for the FA core complex in REV1-mediated TLS has
been demonstrated (11): FANCA and FANCG, yet not
FANCD2, were demonstrated to be required for the efficient
assembly of the REV1 protein into nuclear foci (11). It has
recently been proposed that themono-ubiquitination of PCNA
may be required for a post-replicative DNA repair process, for
example daughter-strand gap (DSG) repair (12, 42, 43). AsDSG
repair is thought to involve both TLS and a HR-mediated tem-
plate switching process (12, 43), we propose a model whereby
FANCD2 and PCNA, through amono-ubiquitination-depend-
ent process,may function in theHR repair ofDSGs (Fig. 7). This
is consistent with several studies indicating a role for the FA
proteins in an undefined HR process, as well as earlier observa-
tions that the major HR proteins BRCA1, FANCD1/BRCA2,
and RAD51, co-localize with PCNA and FANCD2 in nuclear
foci during S-phase (44, 45).
In summary, our findings strongly suggest that the FANCD2
protein associates with PCNA in a DNA damage surveillance
capacity via a highly conserved PIP-box. Upon encounter of a
lesion-damaged template during DNA replication, PCNA-as-
sociated FANCD2 becomes mono-ubiquitinated via the con-
certed activity of the core FA complex, the FANCL ubiquitin
ligase, and the UBE2T E2 ubiquitin-conjugating enzyme, thus
facilitating its function in DNA repair. The erroneous or
untimely repair of damaged DNA replication forks could lead
to the generation of the complex, unbalanced chromosomal
abnormalities frequently observed in FA cancer cells. Our find-
ings have significant implications for our understanding of the
DNA damage surveillance and repair mechanisms activated
upon DNA replication fork arrest, and lend further insight into
the molecular etiology of a rare, yet highly important, cancer
susceptibility syndrome.
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FIGURE 7. A speculative model depicting mono-ubiquitination-depend-
ent and independent functions of the FA-BRCA pathway in DNA replica-
tion-associated repairprocesses. In response toDNAdamageencountered
by the DNA replisome, the FA core complex (a) promotes the formation of
REV1 nuclear foci in a rapid error-prone TLS pathway (11) and (b) promotes
themono-ubiquitination of FANCD2 and FANCI, which, together withmono-
ubiquitinated PCNA (42), may promote a post-replicative, HR-dependent
DSG repair mechanism.
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SUPPLEMENTAL FIGURE LEGENDS 
FIGURE S1. Co-immunoprecipitation of FANCD2 and PCNA in chromatin. HCT116 cells were 
untreated (NT) or exposed to 40 J/m2 UV irradiation (UV) and allowed to recover for 4 h prior to triton 
extraction and crosslinking as described (17). Triton-soluble (S100) and triton-insoluble (P300) proteins 
were incubated with a rabbit polyclonal antibody against FANCD2 or rabbit serum. Immune complexes 
were resolved and immunoblotted with mouse monoclonal antibodies against FANCD2 and PCNA.  
  
FIGURE S2. Bar charts depicting the quantification of protein band intensities from Figure 2. A, 
Quantification of protein band intensities from Figure 2B, demonstrating the decreased association 
between PCNA and the FANCD2 PIPΔ mutant. B, Quantification of protein band intensities from Figure 
2C, demonstrating the decreased association between PCNA and the 6xHis/V5-FANCD2 PIPΔ mutant. C, 
Quantification of protein band intensities from Figure 2D, demonstrating approximately equal levels of 
association between FLAG-FANCE and FANCD2 wt, FANCD2 K561R, and FANCD2 PIPΔ. The white 
bars represent values from the input bands (W) while the black bars represent values from the 
immunprecipitation bands (IP). Protein band intensities were quantified using Scion Image.  
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